The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
BMC Biol. 2011 Oct 28;9:72. doi: 10.1186/1741-7007-9-72.
Current interest in proteasome inhibitors for cancer therapy has stimulated considerable research efforts to identify the molecular pathway to their cytotoxicity with a view to identifying the mechanisms of sensitivity and resistance as well as informing the development of new drugs. Zhao and Vuori describe this month in BMC Biology experiments indicating a novel role of the adaptor protein p130Cas in sensitivity to apoptosis induced not only by proteasome inhibitors but also by the unrelated drug doxorubicin.
目前，蛋白酶体抑制剂在癌症治疗方面受到广泛关注，这激发了大量研究工作，旨在确定其细胞毒性的分子途径，以鉴定敏感性和耐药性的机制，并为新药开发提供信息。Zhao 和 Vuori 在本月的 BMC 生物学杂志上描述了实验结果，该结果表明衔接蛋白 p130Cas 在对蛋白酶体抑制剂和不相关药物阿霉素诱导的细胞凋亡的敏感性中具有新的作用。
